Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study

BackgroundEsophageal squamous cell carcinoma (ESCC) remains a challenging malignant tumor with poor prognosis and limited treatment methods worldwide, and most patients are at a locally advanced stage at diagnosis. High recurrence and metastasis rates remain the main factors leading to the failure o...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Wenwu He, Chenghao Wang, Lei Wu, Gang Wan, Baisen Li, Yongtao Han, Haojun Li, Xuefeng Leng, Kunyi Du, Haijun Chen, Qifeng Wang, Lin Peng
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Frontiers Media S.A. 2022-06-01
Schriftenreihe:	Frontiers in Immunology
Schlagworte:	neoadjuvant chemoradiotherapy neoadjuvant chemoimmunotherapy total neoadjuvant therapy esophageal squamous cell carcinoma tislelizumab protocol
Online-Zugang:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.853922/full
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!